A. Szegedi

发表

Depressive factors and their relationships with other symptom domains in schizophrenia, schizoaffective disorder, and psychotic depression.

M. Müller, A. Szegedi, H. Wetzel, 2001, Schizophrenia bulletin.

Acute treatment of moderate to severe depression with hypericum extract WS 5570 (St John's wort): randomised controlled double blind non-inferiority trial versus paroxetine

A. Szegedi, R. Kohnen, A. Dienel, 2005, BMJ : British Medical Journal.

Comparison of Hypericum Extract WS® 5570 and Paroxetine in Ongoing Treatment after Recovery from an Episode of Moderate to Severe Depression: Results from a Randomized Multicenter Study

A. Szegedi, R. Kohnen, M. Kieser, 2006, Pharmacopsychiatry.

The catechol-O-methyltransferase Val108/158Met polymorphism affects short-term treatment response to mirtazapine, but not to paroxetine in major depression

R Kohnen, D. Rujescu, H. Stassen, 2005, The Pharmacogenomics Journal.

The MAOA T941G polymorphism and short‐term treatment response to mirtazapine and paroxetine in major depression

D. Rujescu, H. Stassen, N. Dahmen, 2007, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.

Activity of the adenylyl cyclase in lymphocytes of male alcoholic patients is state dependent.

N. Dahmen, M. Müller, A. Szegedi, 1998, Alcoholism, clinical and experimental research.

A monoamine oxidase B gene variant and short-term antidepressant treatment response

Matthias J. Müller, D. Rujescu, H. Stassen, 2007, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

A randomized placebo-controlled trial of asenapine for the prevention of relapse of schizophrenia after long-term treatment.

J. Kane, A. Szegedi, J. Panagides, 2011, The Journal of clinical psychiatry.

Pharmacokinetic interactions of clozapine with selective serotonin reuptake inhibitors: differential effects of fluvoxamine and paroxetine in a prospective study.

A. Szegedi, H. Wetzel, I. Anghelescu, 1998, Journal of clinical psychopharmacology.

Combination treatment with clozapine and paroxetine in schizophrenia: safety and tolerability data from a prospective open clinical trial

A. Szegedi, H. Wetzel, I. Anghelescu, 1998, European Neuropsychopharmacology.

Add-On Combination and Maintenance Treatment: Case Series of Five Obese Patients with Different Eating Behavior

A. Szegedi, I. Anghelescu, C. Klawe, 2002, Journal of clinical psychopharmacology.

Minimum effective dose for antidepressants - an obligatory requirement for antidepressant drug evaluation?

A. Szegedi, H. Wetzel, O. Benkert, 1996, International clinical psychopharmacology.

Comparison of somnolence associated with asenapine, olanzapine, risperidone, and haloperidol relative to placebo in patients with schizophrenia or bipolar disorder

A. Szegedi, K. Gao, M. Mackle, 2013, Neuropsychiatric disease and treatment.

Early improvement as a predictor of acute treatment outcome in manic or mixed episodes in bipolar-1 disorder: a pooled, post hoc analysis from the asenapine development program.

R. McIntyre, A. Szegedi, Jun Zhao, 2013, Journal of affective disorders.

Validation of a 4‐item Negative Symptom Assessment (NSA‐4): a short, practical clinical tool for the assessment of negative symptoms in schizophrenia

A. Szegedi, L. Alphs, C. Coon, 2011, International journal of methods in psychiatric research.

Asenapine Versus Olanzapine in People With Persistent Negative Symptoms of Schizophrenia

R. Buchanan, A. Szegedi, L. Alphs, 2012, Journal of clinical psychopharmacology.

Association analysis between variants of the interleukin-1β and the interleukin-1 receptor antagonist gene and antidepressant treatment response in major depression

Matthias J. Müller, D. Rujescu, H. Stassen, 2008, Neuropsychiatric disease and treatment.

Combination treatment with nefazodone and cognitive-behavioral therapy for relapse prevention in alcohol-dependent men: a randomized controlled study.

Matthias J. Müller, T. Wobrock, A. Scheurich, 2004, The Journal of clinical psychiatry.

Symptom-Triggered versus Standard Chlormethiazole Treatment of Inpatient Alcohol Withdrawal: Clinical Implications from a Chart Analysis

Matthias J. Müller, A. Szegedi, H. Wetzel, 2003, European Addiction Research.

Carbohydrate-deficient transferrin (CDT) and HDL cholesterol (HDL) are highly correlated in male alcohol dependent patients.

A. Szegedi, H. Wetzel, H. Himmerich, 2000, Alcoholism, clinical and experimental research.

Dose escalation vs. continued doses of paroxetine and maprotiline: a prospective study in depressed out‐patients with inadequate treatment response

A. Szegedi, H. Wetzel, O. Benkert, 1997, Acta psychiatrica Scandinavica.

Is there a common resilience mechanism underlying antidepressant drug response? Evidence from 2848 patients.

H. Stassen, D. Hell, A. Szegedi, 2007, The Journal of clinical psychiatry.

No association of alcohol dependence with a NMDA-receptor 2B gene variant

D. Rujescu, I. Giegling, S. Wiemann, 2003, Molecular Psychiatry.

Reliability and validity of the German version of the European Addiction Severity Index (EuropASI).

Matthias J. Müller, A. Scheurich, M. Hautzinger, 2000, Journal of studies on alcohol.

Sex differences in allelic frequencies of the 5‐HT2C Cys23Ser polymorphism in psychiatric patients and healthy volunteers: findings from an association study

N. Dahmen, A. Szegedi, I. Anghelescu, 2000, Psychiatric genetics.

Effects of vilazodone on sexual functioning in healthy adults: results from a randomized, double-blind, placebo-controlled, and active-controlled study

A. Szegedi, Laishun Chen, S. Durgam, 2016, International clinical psychopharmacology.

Effect of Reversal of Neuromuscular Blockade with Sugammadex versus Usual Care on Bleeding Risk in a Randomized Study of Surgical Patients

H. Fennema, A. Szegedi, M. Blobner, 2014, Anesthesiology.

No association between the dopamine d2 receptor taqi a1 allele and earlier age of onset of alcohol dependence according to different specified criteria.

N. Dahmen, A. Szegedi, H. Wetzel, 2001, Alcoholism, clinical and experimental research.

Adenylyl cyclase activity is increased in younger, but decreased in older, alcoholic patients after detoxification.

N. Dahmen, A. Szegedi, H. Wetzel, 2000, Alcohol and alcoholism.

Blood ethanol levels and adenylyl cyclase activity in lymphocytes of alcoholic patients

N. Dahmen, A. Szegedi, H. Wetzel, 1999, Biological Psychiatry.

Efficacy of ubrogepant based on prior exposure and response to triptans: A post hoc analysis

A. Szegedi, D. Dodick, P. Goadsby, 2021, Headache.

Antisocial Personality Disorder and its Correlate in the Michigan Alcoholism Screening Test

Matthias J. Müller, A. Scheurich, M. Planck, 2004 .

Alcohol dependence is associated with a NMDA-receptor 2B gene variant

D. Rujescu, I. Giegling, S. Wiemann, 2001, European Psychiatry.

Piracetam in the treatment of tardive dyskinesia and akathisia: a case report.

N. Dahmen, A. Szegedi, C. Fehr, 2001, Journal of clinical psychopharmacology.

Safety and tolerability of ubrogepant following intermittent, high-frequency dosing: Randomized, placebo-controlled trial in healthy adults

P. Watkins, A. Szegedi, L. Severt, 2019, Cephalalgia : an international journal of headache.

Long-term effects of asenapine or olanzapine in patients with persistent negative symptoms of schizophrenia: A pooled analysis

S. Potkin, A. Szegedi, L. Alphs, 2013, Schizophrenia Research.

Response to treatment in minor and major depression: results of a double-blind comparative study with paroxetine and maprotiline.

A. Szegedi, H. Wetzel, O. Benkert, 1997, Journal of affective disorders.

Effect of Ubrogepant vs Placebo on Pain and the Most Bothersome Associated Symptom in the Acute Treatment of Migraine: The ACHIEVE II Randomized Clinical Trial.

R. Lipton, A. Szegedi, D. Dodick, 2019, JAMA.

Time course of efficacy of ubrogepant for the acute treatment of migraine: Clinical implications

R. Lipton, A. Szegedi, D. Dodick, 2020, Cephalalgia : an international journal of headache.

Addition of Low-Dose Fluvoxamine to Low-Dose Clozapine Monotherapy in Schizophrenia: Drug Monitoring and Tolerability Data from a Prospective Clinical Trial

A. Szegedi, H. Wetzel, I. Anghelescu, 1999, Pharmacopsychiatry.

Improved efficacy and fewer side effects under clozapine treatment after addition of fluvoxamine.

A. Szegedi, C. Hiemke, J. Wiesner, 1995, Journal of clinical psychopharmacology.

Automated Determination of Paroxetine and Its Main Metabolite by Column Switching and On‐Line High‐Performance Liquid Chromatography

A. Szegedi, C. Hiemke, S. Härtter, 1994, Therapeutic drug monitoring.

Neuropsychological status of alcohol-dependent patients: increased performance through goal-setting instructions.

Matthias J. Müller, A. Scheurich, M. Hautzinger, 2004, Alcohol and alcoholism.

Vitamin B12 and hepatic enzyme serum levels correlate in male alcohol-dependent patients.

A. Szegedi, H. Himmerich, I. Anghelescu, 2001, Alcohol and alcoholism.

VITAMIN B 12 AND HEPATIC ENZYME SERUM LEVELS CORRELATE IN MALE ALCOHOL-DEPENDENT PATIENTS

A. Szegedi, H. Himmerich, I. Anghelescu, 2022 .

Superior efficacy of St John's wort extract WS®5570 compared to placebo in patients with major depression: a randomized, double-blind, placebo-controlled, multi-center trial [ISRCTN77277298]

S. Kasper, A. Szegedi, A. Dienel, 2006 .

Systematic analysis of glutamatergic neurotransmission genes in alcohol dependence and adolescent risky drinking behavior.

D. Rujescu, S. Cichon, I. Giegling, 2008, Archives of general psychiatry.

Weight change and metabolic effects of asenapine in patients with schizophrenia and bipolar disorder.

A. Szegedi, D. Kemp, M. Mackle, 2014, The Journal of clinical psychiatry.

Meta-analyses of the efficacy of asenapine for acute schizophrenia: comparisons with placebo and other antipsychotics.

H. Fennema, A. Szegedi, P. Verweij, 2012, The Journal of clinical psychiatry.

Association of a MAOA gene variant with generalized anxiety disorder, but not with panic disorder or major depression

D. Rujescu, I. Giegling, H. Möller, 2003, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.

Hamilton depression rating subscales to predict antidepressant treatment outcome in the early course of treatment.

A. Szegedi, R. Kohnen, I. Helmreich, 2015, Journal of affective disorders.

Mirtazapine: a review of its clinical efficacy and tolerability

A. Szegedi, N. Schwertfeger, Natascha Schwertfeger, 2005, Expert opinion on pharmacotherapy.

Deep Neuromuscular Blockade Improves Laparoscopic Surgical Conditions: A Randomized, Controlled Study

H. Fennema, J. Rosenberg, A. Szegedi, 2017, Advances in Therapy.

Ubrogepant for the Treatment of Migraine.

R. Lipton, A. Szegedi, D. Dodick, 2019, The New England journal of medicine.

Serotonergic polymorphisms in patients suffering from alcoholism, anxiety disorders and narcolepsy

N. Dahmen, A. Szegedi, C. Hiemke, 2001, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

Pramipexole, a Dopamine Agonist, in Major Depression: Antidepressant Effects and Tolerability in an Open‐Label Study with Multiple Doses

W. Gaebel, A. Szegedi, H. Wetzel, 1997 .

Confirmation of association of the GABRA2 gene with alcohol dependence by subtype-specific analysis

N. Dahmen, A. Szegedi, T. Sander, 2006, Psychiatric genetics.

Cue exposure in alcohol dependent patients: preliminary evidence for different types of cue reactivity

A. Scheurich, M. Hautzinger, A. Szegedi, 2000, Journal of Neural Transmission.

Effects of asenapine on depressive symptoms in patients with bipolar I disorder experiencing acute manic or mixed episodes: a post hoc analysis of two 3-week clinical trials

A. Szegedi, A. V. van Willigenburg, J. Panagides, 2011, BMC psychiatry.

The Selective Glycine Uptake Inhibitor Org 25935 as an Adjunctive Treatment to Atypical Antipsychotics in Predominant Persistent Negative Symptoms of Schizophrenia: Results From the GIANT Trial

A. Szegedi, J. Schipper, J. Schoemaker, 2014, Journal of clinical psychopharmacology.

What does the HAMD mean?

Peter Lepping, Stefan Leucht, H. Fennema, 2013, Journal of affective disorders.

GRIN1 locus may modify the susceptibility to seizures during alcohol withdrawal

D. Rujescu, I. Giegling, H. Möller, 2005, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.

Syndrome profiles in alcoholism and panic disorder with or without agoraphobia An explorative family study

Matthias J. Müller, A. Szegedi, O. Benkert, 2002, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

A Translational Approach to Evaluate the Efficacy and Safety of the Novel AMPA Receptor Positive Allosteric Modulator Org 26576 in Adult Attention-Deficit/Hyperactivity Disorder

F. Tarazi, A. Szegedi, L. Adler, 2012, Biological Psychiatry.

Asenapine for the Acute Treatment of Pediatric Manic or Mixed Episode of Bipolar I Disorder.

K. Chang, A. Szegedi, R. Findling, 2015, Journal of the American Academy of Child and Adolescent Psychiatry.

Seroquel (ICI 204 636), a putative “atypical” antipsychotic, in schizophrenia with positive symptomatology: results of an open clinical trial and changes of neuroendocrinological and EEG parameters

A. Szegedi, H. Wetzel, O. Benkert, 1995, Psychopharmacology.

Distigmine bromide induced acute psychotic disorder in a patient with multiple sclerosis

Matthias J. Müller, A. Szegedi, H. Himmerich, 2003, European Psychiatry.

Risperidone versus haloperidol and amitriptyline in the treatment of patients with a combined psychotic and depressive syndrome.

A. Szegedi, H. Wetzel, O. Benkert, 1998, Journal of clinical psychopharmacology.

Topiramate in venlafaxine-induced visual hallucinations in an obese patient with a posterior cerebral artery infarction.

A. Szegedi, H. Himmerich, I. Anghelescu, 2001, Journal of clinical psychopharmacology.

OnabotulinumtoxinA for the treatment of major depressive disorder: a phase 2 randomized, double-blind, placebo-controlled trial in adult females

M. Brin, M. Thase, A. Szegedi, 2019, International clinical psychopharmacology.

[Combination treatment with SSRI and cognitive behavior therapy for relapse prevention of alcohol-dependent men. Results of a randomized, controlled multicenter therapeutic study].

T. Wobrock, A. Scheurich, M. Hautzinger, 2005, Der Nervenarzt.

Early improvement in the first 2 weeks as a predictor of treatment outcome in patients with major depressive disorder: a meta-analysis including 6562 patients.

Hans H Stassen, M. Thase, H. Stassen, 2009, The Journal of clinical psychiatry.

The HTR1B 861G>C receptor polymorphism among patients suffering from alcoholism, major depression, anxiety disorders and narcolepsy

N. Dahmen, A. Szegedi, C. Hiemke, 2000, Psychiatry Research.

A prepro-orexin gene polymorphism is associated with narcolepsy

N. Dahmen, A. Szegedi, J. Bierbrauer, 2001, Neurology.

Association of VMAT2 gene polymorphisms with alcohol dependence

N. Dahmen, A. Szegedi, P. Zill, 2013, Journal of Neural Transmission.

Combination treatment with clomipramine and fluvoxamine: drug monitoring, safety, and tolerability data.

A. Szegedi, H. Wetzel, C. Hiemke, 1996, The Journal of clinical psychiatry.

Safety, tolerability, and efficacy of orally administered atogepant for the prevention of episodic migraine in adults: a double-blind, randomised phase 2b/3 trial

A. Szegedi, D. Dodick, P. Goadsby, 2020, The Lancet Neurology.

Early improvement under mirtazapine and paroxetine predicts later stable response and remission with high sensitivity in patients with major depression.

Matthias J. Müller, A. Szegedi, O. Benkert, 2003, The Journal of clinical psychiatry.

Unipolar depressive Störungen

A. Szegedi, O. Benkert, F. Regen, 2012 .

Differentiating moderate and severe depression using the Montgomery-Asberg depression rating scale (MADRS).

Hubertus Himmerich, Matthias J. Müller, A. Szegedi, 2003, Journal of affective disorders.

Clinical value of early partial symptomatic improvement in the prediction of response and remission during short-term treatment trials in 3369 subjects with bipolar I or II depression.

Hans H Stassen, Joseph R Calabrese, Stephen J Ganocy, 2011, Journal of affective disorders.

Three dimensions of depression in patients with acute psychotic disorders: a replication study.

A. Szegedi, H. Wetzel, O. Benkert, 1999, Comprehensive psychiatry.

Mirtazapine compared with paroxetine in major depression.

A. Szegedi, O. Benkert, R. Kohnen, 2000, The Journal of clinical psychiatry.

Low novelty seeking and high self directedness scores in alcohol-dependent patients without comorbid psychiatric disorders homozygous for the A10 allele of the dopamine transporter gene

N. Dahmen, A. Szegedi, A. Quante, 2010 .

Low novelty seeking and high self directedness scores in alcohol-dependent patients without comorbid psychiatric disorders homozygous for the A10 allele of the dopamine transporter gene.

N. Dahmen, A. Szegedi, A. Quante, 2010, The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry.

The primary care evaluation of mental disorders (PRIME-MD), German version: a comparison with the CIDI.

A. Szegedi, O. Benkert, R. Kohnen, 2000, Journal of psychiatric research.

Asenapine as Adjunctive Treatment for Acute Mania Associated With Bipolar Disorder: Results of a 12-Week Core Study and 40-Week Extension

J. Calabrese, A. Szegedi, J. Panagides, 2012, Journal of clinical psychopharmacology.

Analysis of genetic variations of protein tyrosine kinase fyn and their association with alcohol dependence in two independent cohorts

D. Rujescu, I. Giegling, A. Poustka, 2003, Biological Psychiatry.

Randomized, Double-Blind, Placebo-Controlled Trial of Asenapine Maintenance Therapy in Adults With an Acute Manic or Mixed Episode Associated With Bipolar I Disorder.

A. Szegedi, S. Durgam, M. Mathews, 2018, The American journal of psychiatry.

Tyrosine hydroxylase Val-81-Met polymorphism associated with early-onset alcoholism

N. Dahmen, A. Szegedi, C. Hiemke, 2005, Psychiatric genetics.

Evaluation of the glycine transporter inhibitor Org 25935 as augmentation to cognitive-behavioral therapy for panic disorder: a multicenter, randomized, double-blind, placebo-controlled trial.

B. Rothbaum, S. Hofmann, M. Otto, 2012, The Journal of clinical psychiatry.

Efficacy and safety of the glycine transporter-1 inhibitor org 25935 for the prevention of relapse in alcohol-dependent patients: a randomized, double-blind, placebo-controlled trial.

A. Szegedi, B. Söderpalm, J. Schoemaker, 2014, Alcoholism, clinical and experimental research.

Moderate and severe depression. Gradations for the Montgomery-Asberg Depression Rating Scale.

A. Szegedi, H. Wetzel, O. Benkert, 2000, Journal of affective disorders.

Serotonin dysfunction syndromes: a functional common denominator for classification of depression, anxiety, and obsessive‐compulsive disorder

A. Szegedi, H. Wetzel, O. Benkert, 1993, International clinical psychopharmacology.

Predicting stable treatment response in patients with major depression treated with hypericum extract WS 5570/5572.

A. Szegedi, M. Kieser, 2005, Pharmacopsychiatry.

Translating the HAM-D into the MADRS and vice versa with equipercentile linking.

H. Fennema, S. Leucht, A. Szegedi, 2018, Journal of affective disorders.

P.3.c.057 Double-blind, placebo-controlled trial of asenapine in prevention of relapse after long-term treatment of schizophrenia

A. Szegedi, J. Zhao, J. Panagides, 2009, European Neuropsychopharmacology.

Reliability and Validity of the Form 90 Interview

A. Scheurich, M. Hautzinger, A. Szegedi, 2004, European Addiction Research.

Predicting Response to Psychopharmacological Treatment: Survey of Recent Results

D. Rujescu, H. Stassen, A. Szegedi, 2011, Pharmacopsychiatry.

Modeling activation of inflammatory response system: a molecular-genetic neural network analysis

H. Stassen, A. Szegedi, C. Scharfetter, 2007, BMC proceedings.

What does the MADRS mean? Equipercentile linking with the CGI using a company database of mirtazapine studies.

H. Fennema, S. Leucht, A. Szegedi, 2017, Journal of affective disorders.

Asenapine effects on individual Young Mania Rating Scale items in bipolar disorder patients with acute manic or mixed episodes: a pooled analysis

A. Szegedi, M. Mackle, Jun Zhao, 2013, Neuropsychiatric disease and treatment.

PW01-28 - Asenapine as Adjunctive Treatment For Bipolar Mania: A Placebo-controlled 12-week Study and 40-week Extension

A. Szegedi, J. Zhao, J. Panagides, 2010, European psychiatry.

Placebo controlled continuation treatment with Hypericum extract WS® 5570 after recovery from a mild or moderate depressive episode

S. Kasper, A. Szegedi, A. Dienel, 2007, Wiener Medizinische Wochenschrift.

ASENAPINE VERSUS OLANZAPINE IN PATIENTS WITH PREDOMINANT PERSISTENT NEGATIVE SYMPTOMS OF SCHIZOPHRENIA

R. Buchanan, A. Szegedi, J. Panagides, 2008, Schizophrenia Research.

Polymorphisms in the NMDA subunit 2B are not associated with alcohol dependence and alcohol withdrawal–induced seizures and delirium tremens

D. Rujescu, I. Giegling, N. Dahmen, 2005, European Archives of Psychiatry and Clinical Neuroscience.

Mirtazapine Orally Disintegrating Tablets Versus Venlafaxine Extended Release: A Double-blind, Randomized Multicenter Trial Comparing the Onset of Antidepressant Response in Patients With Major Depressive Disorder

A. Szegedi, O. Benkert, R. Kohnen, 2006, Journal of clinical psychopharmacology.

Normal PET after long-term ECT.

A. Szegedi, I. Anghelescu, C. Klawe, 2001, The American journal of psychiatry.

Rapid onset of therapeutic action in major depression: A comparative trial of mirtazapine and paroxetine

A. Szegedi, O. Benkert, R. Kohnen, 1999, European Neuropsychopharmacology.

Addition of an NK1 receptor antagonist to an SSRI did not enhance the antidepressant effects of SSRI monotherapy: results from a randomized clinical trial in patients with major depressive disorder

C. Lines, A. Szegedi, R. Hargreaves, 2014, Human psychopharmacology.

Evaluation of standardized rater training for the Positive and Negative Syndrome Scale (PANSS)

Matthias J. Müller, A. Szegedi, H. Wetzel, 1998, Schizophrenia Research.

Superior efficacy of St John's wort extract WS®5570 compared to placebo in patients with major depression: a randomized, double-blind, placebo-controlled, multi-center trial [ISRCTN77277298]

A. Szegedi, A. Dienel, M. Kieser, 2006 .

Association Study of Suicidal Behavior and Affective Disorders with a Genetic Polymorphism in ABCG1, a Positional Candidate on Chromosome 21q22.3

D. Rujescu, I. Giegling, A. Gietl, 2000 .

Safety and tolerability of switching to asenapine from other antipsychotic agents: pooled results from two randomized multicenter trials in stable patients with persistent negative symptoms in schizophrenia

A. Szegedi, X. Ha, M. Mackle, 2012, Neuropsychiatric disease and treatment.

Association study of suicidal behavior and affective disorders with a genetic polymorphism in ABCG1, a positional candidate on chromosome 21q22.3

D. Rujescu, I. Giegling, H. Möller, 2000, European Neuropsychopharmacology.

Effects of Interrater Reliability of Psychopathologic Assessment on Power and Sample Size Calculations in Clinical Trials

Matthias J. Müller, A. Szegedi, 2002, Journal of clinical psychopharmacology.

OnabotulinumtoxinA for the treatment of major depressive disorder: a phase 2 randomized, double-blind, placebo-controlled trial in adult females.

M. Brin, M. Thase, A. Szegedi, 2020 .

Superior efficacy of St John's wort extract WS® 5570 compared to placebo in patients with major depression: a randomized, double-blind, placebo-controlled, multi-center trial [ISRCTN77277298]

S. Kasper, A. Szegedi, A. Dienel, 2006, BMC medicine.

Acute treatment of moderate to severe depression with hypericum extract WS 5570 (St John's wort): randomised controlled double blind non-inferiority trial versus paroxetine

A. Szegedi, R. Kohnen, A. Dienel, 2005, BMJ : British Medical Journal.

Asenapine as Adjunctive Treatment for Acute Mania Associated With Bipolar Disorder: Results of a 12-Week Core Study and 40-Week Extension

J. Calabrese, A. Szegedi, J. Panagides, 2012, Journal of clinical psychopharmacology.

An overview of the clinical efficacy of mirtazapine

A. Szegedi, O. Benkert, M. Müller, 2002, Human psychopharmacology.

Efficacy, Safety, and Tolerability of Ubrogepant for the Acute Treatment of Migraine: Results From a Single-Attack Phase 3 Study, ACHIEVE II (S38.008)

R. Lipton, A. Szegedi, D. Dodick, 2019, Neurology.

The TPH intron 7 A218C polymorphism and TCI dimension scores in alcohol-dependent patients: hints to nonspecific psychopathology.

N. Dahmen, A. Szegedi, H. Himmerich, 2005, Addictive behaviors.